Friday 6 November 2026 Export KPRX’s income statement to Excel — free account

Kiora Pharmaceuticals, Inc.

KPRX Healthcare Biotechnology

Kiora Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $16.0 million.

EPS: +37.0%
Free cash flow: +50.1%

Quarter to June 2026, against a year earlier

1.42 0.08 −5.33%

Follow KPRX

Alert me

Market cap: $6.6M
P/E: 0.0×
Fwd P/E: −1.2×
Dividend yield: —
F-score: n/a
Altman Z: −3.16
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 36.71%

Capital & Financial Ratios $m

Size

Market Cap 6.63

Revenue ttm 18.72

Net income ttm (10.99)

Free cash flow ttm (8.61)

Net debt Q (16.84)

Valuation

P/E 0.00

Forward P/E (1.22)

Price / sales 0.47

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.52

Financial health

Current ratio Q 8.97

Debt / equity Q 0.00

Interest coverage Q (118.61)

Growth

Revenue growth Q −93.64%

Operating income growth Q +7.61%

EPS, this year +56.82%

EPS, next year A +30.70%

Revenue, next year A −90.64%

EPS, past 5 yrs —

EPS, next 5 yrs A +28.38%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 3.11%

10-year low 10-year high

P/B against its own 10 years 27.84%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	2	27	17	17
Receivables	2	1	3	3
Inventory	—	—	—	—
Other	—	—	0	0
	5	30	22	21

	2023	2024	2025	Q'26
Payables	0	0	1	0
ST’ Debt	—	—	—	—
Other	—	1	—	—
	2	6	4	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	88.72%	113.23%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	10.23%	10.63%	12.23%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY25 Estimate −0.72 Actual 0.01

−1.20 −0.86 −0.51 −0.17 0.17

Q4 FY24 Miss −0.30

Q1 FY25 Beat +0.25

Q2 FY25 Beat +0.04

Q3 FY25 Beat +0.73

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY24	−0.74	−1.04	Miss by 0.30
Q1 FY25	−0.77	−0.52	Beat by 0.25
Q2 FY25	−0.58	−0.54	Beat by 0.04
Q3 FY25	−0.72	0.01	Beat by 0.73

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.58)	(0.34)	—	—	—
’25	(0.52)	(0.54)	0.01	(1.60)	(2.64)
’24	3.42	(0.53)	(0.81)	(1.04)	0.87
’23	(9.00)	(7.11)	(8.01)	(2.87)	(24.21)
’22	(97.21)	(1.65)	(54.27)	(9.53)	(166.97)
’21	(98.38)	(126.01)	(104.41)	(280.83)	(514.08)
’20	(154.81)	(136.81)	(158.42)	(87.74)	(536.40)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	16	0	—	—	16
’20	—	—	—	0	0
’19	3	—	—	—	3
’18	1	0	0	—	2
’17	0	0	0	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(3)	(4)	(1)	(2)	(10)
’24	14	(4)	1	(2)	9
’23	(3)	(1)	(3)	(3)	(10)
’22	(3)	(2)	(3)	(2)	(10)
’21	(3)	(3)	(2)	(3)	(11)
’20	(2)	(1)	(2)	(2)	(7)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(2)	—	—	—
’25	(3)	(4)	(1)	(2)	(10)
’24	14	(4)	1	(2)	9
’23	(3)	(1)	(3)	(3)	(10)
’22	(3)	(2)	(3)	(2)	(10)
’21	(3)	(3)	(2)	(3)	(11)
’20	(2)	(1)	(2)	(2)	(7)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	1	0	2	3	0	—	—	—	16	—	19		+48.7%	23	23	23	0.0%
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	0.00	0.00	—	100.00	—	85.06		0.0 pt	Powerpack Kiora Pharmaceuticals, Inc.’s next three years, line by line Analysts expect revenue to grow 0.0% a year to 2028 — slower than the 48.7% of the last 8 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(13)	(15)	(11)	(7)	(7)	(14)	(14)	(12)	6	(12)	(12)		(1.1%)
	EBT margin, %	(1,993.64)	(3,572.98)	(649.04)	(260.66)	(56,609.09)	0.00	0.00	0.00	35.33	0.00	0.00		+1,993.6 pt
	Net income	(13)	(13)	(11)	(7)	(7)	(14)	(14)	(13)	4	(11)	(11)		(2.3%)
Per share, $
Per share, $	Revenue	418.31	156.73	250.38	305.23	0.95	0.00	0.00	0.00	4.14	0.00	0.00		n/m
	Earnings	(8,150.74)	(5,019.99)	(1,619.35)	(802.88)	(536.40)	(514.08)	(166.97)	(24.21)	0.93	(2.60)	(2.47)		(59.1%)
	Cash flow	(5,258.25)	(2,487.88)	(1,643.11)	(926.57)	(571.66)	(398.34)	(128.27)	(17.76)	2.21	(2.39)	(1.38)		(57.5%)
	Capex	(6.87)	(14.23)	(3.03)	0.00	(1.57)	(2.38)	0.08	0.00	0.00	(0.03)	(0.02)		(46.1%)
	Free cash flow	(5,265.12)	(2,502.12)	(1,646.14)	(926.57)	(573.23)	(400.72)	(128.19)	(17.76)	2.21	(2.42)	(1.39)		(57.4%)
	Book value	(205.87)	(741.12)	1,353.98	752.56	760.13	544.00	140.31	11.36	6.65	3.87	2.73		n/m
	Shares, m	0	0	0	0	0	0	0	1	4	4	5		+139.6%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	—	—	—	1.51	—	0.00		0.3
	P/S	0.00	27.69	9.60	7.32	6.98	—	—	—	0.68	—	0.47		8.7
	P/B	0.00	0.00	1.85	4.79	2.33	—	—	—	0.50	—	0.52		1.6
	EV/Sales	0.00	13.95	4.96	6.45	6.70	—	—	—	(0.74)	—	(0.42)		5.2
	EV/FCF	(1.29)	(1.22)	(0.79)	(3.41)	(2.95)	—	—	—	(1.62)	—	0.92		(1.9)
Cash, $m
Cash, $m	Operating cash flow	(8)	(6)	(11)	(8)	(7)	(11)	(10)	(10)	9	(10)	(9)		+1.9%
	Capex	0	0	0	—	0	0	0	—	0	0	0		+29.3%
	Free cash flow	(8)	(7)	(11)	(8)	(7)	(11)	(10)	(10)	9	(10)	(9)		+2.0%
Balance, $m
Balance, $m	Working capital	(3)	(6)	5	3	0	7	4	3	24	18	19		n/m
	Net debt	(4)	(8)	(8)	(4)	(1)	(8)	(6)	(2)	(27)	(17)	(17)		+18.8%
	Shareholders’ equity	0	(2)	9	7	10	15	11	6	26	16	17		n/m
Returns, %
Returns, %	ROA	(138.72)	(109.98)	(75.64)	(58.19)	(53.99)	(77.72)	(70.00)	(80.55)	14.32	(35.68)	(39.43)		+103.0 pt
	ROIC	0.00	0.00	(727.17)	(156.13)	(48.66)	(132.31)	(141.35)	(215.23)	0.00	0.00	(44,053.91)		0.0 pt
	ROE	(463.52)	1,171.64	(308.49)	(91.23)	(83.93)	(113.30)	(104.54)	(148.94)	22.56	(51.74)	(56.36)		+411.8 pt
People
People	Employees	11	17	11	10	14	14	12	12	12	13	—		+1.9%
	Revenue/emp, $m	0.06	0.02	0.15	0.27	0.00	0.00	0.00	0.00	1.34	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2024 · latest quarter Jun 2024 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MTVA MetaVia Inc.	$7.2M	— (loss-making)	—	—	n/m	−22.42% (below 0%: shrinking)	—	0.00%	Compare
ENSC Ensysce Biosciences, Inc.	$7.0M	— (loss-making)	— (loss-making)	−15.10% (below 0%: shrinking)	n/m	+27.50% (above 0%: growing)	100.00%	(221.28%)	Compare
BCLI Brainstorm Cell Therapeutics Inc.	$7.0M	— (loss-making)	—	—	n/m	+74.44% (above 0%: growing)	0.00%	0.00%	Compare
IMRN IMMURON	$6.9M	— (loss-making)	—	+757.00% (above 0%: growing)	+12.00% (above 0%: growing)	+42.55% (above 0%: growing)	72.16%	0.00%	Compare
SYBX Synlogic, Inc.	$6.7M	— (loss-making)	— (loss-making)	−95.40% (below 0%: shrinking)	n/m	−277.87% (below 0%: shrinking)	100.00%	0.00%	Compare
KPRX Kiora Pharmaceuticals, Inc.	$6.6M	— (loss-making)	— (loss-making)	−93.64% (below 0%: shrinking)	n/m	+50.06% (above 0%: growing)	100.00%	0.00%
FBLG FibroBiologics Inc.	$6.4M	— (loss-making)	—	—	n/m	+21.59% (above 0%: growing)	—	0.00%	Compare
ENVB Enveric Biosciences, Inc.	$6.3M	— (loss-making)	— (loss-making)	−7.28% (below 0%: shrinking)	n/m	−29.34% (below 0%: shrinking)	0.00%	0.00%	Compare
APRE Aprea Therapeutics, Inc.	$6.2M	— (loss-making)	— (loss-making)	−98.40% (below 0%: shrinking)	n/m	−5.22% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$6.8M	—	—	−15.10%	—	+8.19%	86.08%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2026

Ownership

Directors and executive officers, together 0.52%

ADAR1 Capital Management, LLC 9.99%

AIGH Capital Management, LLC 9.99%

Stonepine Capital, L.P. 9.99%

Perceptive Advisors, LLC 9.89%

Rosalind Advisors Inc. 9.49%

Lincoln Park Capital Fund, LLC 9.29%

Nantahala Capital Management, LLC 7.84%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Kiora Pharmaceuticals, Inc. (KPRX) Latest News

29 Oct

Impact 4 · 7:00 AM · TMX Newsfile

Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan

Impact 4 · 6:45 AM · Newsfile

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa

19 Aug

Impact 4 · 7:00 AM

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

7 Aug

Impact 3 · 7:00 AM

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Impact 3 · 7:00 AM · Newsfile

Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

18 Jun

Impact 3 · 7:00 AM

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

8 May

Impact 3 · 7:00 AM · TMX Newsfile

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

14 Apr

Impact 4 · 7:00 AM · TMX Newsfile

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

7 Apr

Impact 4 · 7:00 AM · TMX Newsfile

Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

25 Mar

Impact 4 · 7:00 AM · Newsfile

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027

Impact 3 · 7:00 AM · TMX Newsfile

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials

27 Jan

Impact 4 · 7:00 AM · TMX Newsfile

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

1 Dec

Impact 4 · 6:45 AM · NewsfileSimply Wall St.ZacksPharmaceutical TechnologyMT NewswiresSimply Wall St.Motley FoolMotley Fool

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

7 Nov

Impact 4 · 6:00 AM · NewsfileZacksGuruFocus.comGuruFocus.comZacksGuruFocus.comMT NewswiresGuruFocus.com

Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases

30 Oct

Impact 4 · 9:00 AM · PR Newswire

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

Impact 4 · 7:28 AM · TipRanks

Kiora Pharmaceuticals Gains Approval for Phase 2 Trial

15 Oct

Impact 3 · 7:00 AM · NewsfileMT NewswiresMT NewswiresMT Newswires

Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025

8 Aug

Impact 4 · 7:00 AM

Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases

22 Jul

Impact 4 · 8:55 AM · Newsfile

Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease

16 Jul

Impact 4 · 12:00 PM · Zacks

Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know

3 Jun

Impact 4 · 7:00 AM

Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia

Impact 3 · 1:37 PM

Top Midday Gainers

9 May

Impact 4 · 7:00 AM · Newsfile

Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027

5 May

Impact 4 · 7:00 AM · Newsfile

Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy

12 Mar

Impact 4 · 7:00 AM · Newsfile

Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting

13 Feb

Impact 4 · 7:00 AM · Newsfile

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104

11 Feb

Impact 4 · 6:45 AM · Newsfile

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema

15 Nov

Impact 3 · 6:06 AM · Simply Wall St.

We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative

8 Nov

Impact 4 · 7:00 AM

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies

25 Sep

Impact 3 · 9:55 AM · Newsfile

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Kiora Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 30 April 2026

Ownership

Kiora Pharmaceuticals, Inc. (KPRX) Latest News

29 Oct

19 Aug

7 Aug

18 Jun

8 May

14 Apr

7 Apr

25 Mar

27 Jan

1 Dec

7 Nov

30 Oct

15 Oct

8 Aug

22 Jul

16 Jul

3 Jun

9 May

5 May

12 Mar

13 Feb

11 Feb

15 Nov

8 Nov

25 Sep

Stockrow Weekly